Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 637073
                    [Title] => Roche bares non-Hodgkin's lymphoma study results
                    [Summary] => 
ORLANDO, Florida — Roche announced recently new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory non-Hodgkin’s lymphoma (NHL), a common type of blood cancer.
                    [DatePublished] => 2010-12-09 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

GA101

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 637073
                    [Title] => Roche bares non-Hodgkin's lymphoma study results
                    [Summary] => 
ORLANDO, Florida — Roche announced recently new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory non-Hodgkin’s lymphoma (NHL), a common type of blood cancer.
                    [DatePublished] => 2010-12-09 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche bares non-Hodgkin's lymphoma study results

December 9, 2010 - 12:00am

ORLANDO, Florida — Roche announced recently new Phase II efficacy data from the investigational compound GA101 (RG 1759) in relapsed/refractory non-Hodgkin’s lymphoma (NHL), a common type of blood c...

Science and Environment